Drugs Made In America Acquisition Corp. Ordinary Shares
Financial ServicesNASDAQ:DMAA · NASDAQ Global Select
+$0.01 today
Vol 0.00M · Avg 0.11M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 2 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | $4.0M +828321.9% | -$479 | $521.2M | $510.0M | $498.8M |
| Depreciation & Amortization | $0 | $0 | $990.2M | $419.0M | $1.2B |
| Deferred Income Tax | $0 | $0 | $1.2B | $1.0B | $1.2B |
| Stock-Based Compensation | $0 | $0 | $1.2B | $1.1B | $623.4M |
| Change in Working Capital | $138.8K +104708.3% | $132 | $1.1B | $921.6M | $484.8M |
| Accounts Receivables | $0 | $0 | $939.8M | $559.0M | $1.3B |
| Inventory | $0 | $0 | $518.4M | $686.4M | $854.4M |
| Accounts Payables | $144.9K | $0 | $1.2B | $1.5B | $657.0M |
| Other Working Capital | -$6.1K -4669.7% | $132 | $914.6M | $533.8M | $1.3B |
| Other Non-Cash Items | -$4.6M -2602.0% | -$171.9K | $1.2B | $1.3B | $1.2B |
| Operating Cash Flow | -$539.2K -182675.3% | -$295 | $5.2B | $3.8B | $5.5B |
| Capital Expenditures | $0 -100.0% | $5 | $1.0B | $328.0M | $1.0B |
| Acquisitions (Net) | $0 | $0 | $735.4M | $903.4M | $769.0M |
| Purchases of Investments | $0 | $0 | $847.4M | $713.0M | $578.6M |
| Sales of Investments | $0 | $0 | $329.4M | -$1.5B | $1.0B |
| Other Investing Activities | -$231.2M | $0 | -$1.7B | $1.4B | $862.8M |
| Investing Cash Flow | -$231.2M | $0 | $13.7B | -$15.4B | $3.1B |
| Debt Repayment | -$900.0K -279.2% | $502.2K | -$1.5B | -$1.6B | $602.4M |
| Common Stock Issued | $232.1M +70718.0% | -$328.6K | -$1.7B | $442.8M | $610.8M |
| Common Stock Repurchased | $0 | $0 | $1.1B | $923.0M | $486.2M |
| Dividends Paid | $0 | $0 | $1.4B | $1.5B | -$1.6B |
| Other Financing Activities | $544.0K | $0 | $1.2B | $966.4M | $720.0M |
| Financing Cash Flow | $231.7M +133352.0% | $173.6K | $10.2B | $11.8B | $10.5B |
| Effect of Forex Changes | $0 | $0 | -$1.7B | -$1.5B | $1.4B |
| Net Change in Cash | $4.8K +254.3% | $1.4K | -$15.2B | -$16.8B | -$15.5B |
| Free Cash Flow | -$539.2K -182675.3% | -$295 | $14.7B | $9.0B | $14.3B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Berto Acquisition Corp.
NASDAQ:TACO
$389.82M
Centurion Acquisition Corp.
NASDAQ:ALF
$387.41M
Berto Acquisition Corp. Unit
NASDAQ:TACOU
$374.49M
Titan Acquisition Corp.
NASDAQ:TACH
$358.80M
Oyster Enterprises II Acquisition Corp
NASDAQ:OYSE
$348.64M
SIM Acquisition Corp. I
NASDAQ:SIMA
$333.96M
Renatus Tactical Acquisition Corp I Class A Ordinary Shares
NASDAQ:RTAC
$323.77M
Live Oak Acquisition Corp. V Class A Ordinary Shares
NASDAQ:LOKV
$291.53M
Mountain Lake Acquisition Corp.
NASDAQ:MLAC
$96.70M
SEC Filings
Recent regulatory filings
No filings found.
Does DMAA generate free cash flow?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) generated -$539,187.00 of free cash flow in fiscal 2025.
How much operating cash flow does DMAA produce?
Operating cash flow was -$539,187.00, before capital expenditures of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.